NCT04897022 2026-03-12
A Study of Pembrolizumab and Radiation Therapy in People With Mesothelioma
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
Clinical Trials
16 trialsNCT02959463 2026-03-06
Pembrolizumab After Radiation Therapy in Treating Patients With Pleural Malignant Mesothelioma
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT03760575 2025-12-04
Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)
Abramson Cancer Center at Penn Medicine
Phase 1 Recruiting
NCT04914897 2025-10-02
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)
Sanofi
Phase 2 Terminated
NCT05714553 2025-07-18
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
NuCana plc
Phase 1/2 Terminated
NCT05086692 2025-07-09
ABILITY-1
Medicenna Therapeutics, Inc.
Phase 1/2 Recruiting
NCT02399371 2025-06-11
Pembrolizumab in Treating Patients With Malignant Mesothelioma
University of Chicago
Phase 2 Active not recruiting
NCT06318286 2025-05-25
PENINSULA
Hyogo Medical University
Phase 2 Recruiting
NCT04287829 2024-11-05
PEMMELA
The Netherlands Cancer Institute
Phase 2 Active not recruiting
NCT03546426 2024-10-01
MESOVAX
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 1 Active not recruiting
NCT02707666 2024-07-31
A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma
University of Chicago
Phase 1 Terminated
NCT05425576 2024-03-15
OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Respond to Checkpoint Inhibition
Mateon Therapeutics
Phase 2 Not yet recruiting
NCT03233724 2023-05-31
Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT03654833 2023-03-14
MiST
University of Leicester
Phase 2 Unknown
NCT04201145 2020-11-17
Pembrolizumab + Defactinib In Pleural Mesothelioma
Dana-Farber Cancer Institute
Phase 1 Withdrawn
NCT03175172 2019-04-04
Evaluation of CRS-207 With Pembrolizumab in Previously Treated Malignant Pleural Mesothelioma (MPM)
Aduro Biotech, Inc.
Phase 2 Terminated